Vistagen To Report Second Quarter Financial Results and Host Corporate Update Conference Call on November 9, 2023
November 06 2023 - 7:00AM
Business Wire
Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical
company aiming to transform the treatment landscape for individuals
living with anxiety, depression, and other central nervous system
(CNS) disorders, today announced it will host a conference call and
webcast on Thursday, November 9, 2023, at 2:00 p.m. Pacific Time
(5:00 p.m. Eastern Time) to provide a corporate update and report
results for its fiscal year 2024 second quarter ended September 30,
2023.
Event: Vistagen Fiscal Year 2024 Second Quarter Corporate
Update Conference Call Date: Thursday, November 9, 2023
Time: 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) US
Dial-in (Toll-free): 1-800-245-3047 TOLL/International
Dial-in: 1-203-518-9765 Conference ID: 11153994
Webcast:
https://viavid.webcasts.com/starthere.jsp?ei=1641124&tp_key=2213157260
An audio webcast of the conference call will also be available
via the link provided above. Participants should access this
webcast site 10 minutes before the start of the call. In addition,
a telephone playback of the call will be available after
approximately 5:00 p.m. Pacific Time (8:00 p.m. Eastern Time) on
Thursday, November 9, 2023. To listen to the replay, call toll-free
1-844-512-2921 within the United States or 1-412-317-6671 when
calling internationally (toll). Please use the replay access ID
number: 11153994.
About Vistagen
Vistagen (Nasdaq: VTGN) is a late clinical-stage
biopharmaceutical company aiming to transform the treatment
landscape for individuals living with anxiety, depression, and
other CNS disorders. Vistagen is advancing therapeutics with the
potential to be faster-acting, and with fewer side effects and
safety concerns, than those currently available for the treatment
of anxiety, depression, and multiple CNS disorders. Vistagen's
pipeline includes six clinical-stage product candidates, including
fasedienol (PH94B), itruvone (PH10), PH80, PH15, and PH284, each an
investigational agent belonging to a new class of drugs known as
pherines, as well as AV-101, which is an oral prodrug of an
antagonist of the N-methyl-D-aspartate receptor (NMDAR). Pherines
are neuroactive nasal sprays designed with an innovative proposed
mechanism of action that activates chemosensory neurons in the
nasal cavity and can beneficially impact key neural circuits in the
brain without systemic absorption or direct activity on neurons in
the brain. Vistagen is passionate about transforming mental health
care and redefining what is possible in the treatment of anxiety,
depression, and several other CNS disorders. Connect at
www.Vistagen.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231106711502/en/
Investors Mark A. McPartland Senior Vice President,
Investor Relations (650) 577-3606 markmcp@vistagen.com
Media Nate Hitchings SKDK nhitchings@skdknick.com
Vistagen Therapeutics (NASDAQ:VTGN)
Historical Stock Chart
From Apr 2024 to May 2024
Vistagen Therapeutics (NASDAQ:VTGN)
Historical Stock Chart
From May 2023 to May 2024